|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- September 24, 2008
CopyrightCOPYRIGHT 2008 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Affitech AS, of Oslo, Norway, said that it has accomplished the second milestone in its research and licensing collaboration with F. Hoffmann-La Roche Ltd., of Basel, Switzerland, to produce fully human recombinant antibodies against an unnamed oncology target. Affitech would receive additional milestone payments upon successful development by Roche and royalties on worldwide net sales of any successfully developed product candidates.
ARCA Biopharma Inc., of Broomfield, Colo., said that FDA accepted a new drug application for the company's lead product candidate, bucindolol, an investigational beta-blocker and mild vasodilator developed for the treatment of ...